| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Parkinson Disease | 109 | 2025 | 846 | 20.180 |
Why?
|
| alpha-Synuclein | 52 | 2025 | 132 | 12.980 |
Why?
|
| Genetic Therapy | 38 | 2023 | 85 | 9.080 |
Why?
|
| Neurons | 61 | 2023 | 342 | 8.340 |
Why?
|
| Huntington Disease | 21 | 2021 | 51 | 5.840 |
Why?
|
| Animals | 147 | 2023 | 3812 | 5.780 |
Why?
|
| Dopaminergic Neurons | 17 | 2020 | 50 | 5.570 |
Why?
|
| Substantia Nigra | 41 | 2023 | 124 | 5.430 |
Why?
|
| Disease Models, Animal | 53 | 2021 | 625 | 5.260 |
Why?
|
| Corpus Striatum | 32 | 2020 | 65 | 4.940 |
Why?
|
| Neurturin | 17 | 2023 | 23 | 4.320 |
Why?
|
| Multiple System Atrophy | 12 | 2025 | 38 | 4.060 |
Why?
|
| Genetic Vectors | 27 | 2021 | 60 | 3.620 |
Why?
|
| Dependovirus | 23 | 2021 | 40 | 3.490 |
Why?
|
| Dopamine | 29 | 2023 | 87 | 3.090 |
Why?
|
| Brain | 27 | 2022 | 1695 | 2.990 |
Why?
|
| Neuroprotective Agents | 16 | 2020 | 55 | 2.970 |
Why?
|
| Nerve Degeneration | 13 | 2021 | 49 | 2.830 |
Why?
|
| Lewy Bodies | 13 | 2022 | 194 | 2.800 |
Why?
|
| Nerve Growth Factors | 11 | 2018 | 37 | 2.770 |
Why?
|
| Tyrosine 3-Monooxygenase | 30 | 2023 | 53 | 2.690 |
Why?
|
| Parkinsonian Disorders | 14 | 2021 | 227 | 2.630 |
Why?
|
| Humans | 148 | 2025 | 28560 | 2.570 |
Why?
|
| Brain Tissue Transplantation | 10 | 2017 | 18 | 2.370 |
Why?
|
| Neostriatum | 8 | 2020 | 14 | 2.350 |
Why?
|
| Fetal Tissue Transplantation | 11 | 2017 | 25 | 2.200 |
Why?
|
| Rats | 36 | 2023 | 686 | 2.180 |
Why?
|
| Induced Pluripotent Stem Cells | 5 | 2020 | 19 | 2.140 |
Why?
|
| Putamen | 10 | 2020 | 21 | 2.140 |
Why?
|
| Nerve Tissue Proteins | 19 | 2016 | 156 | 2.030 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 6 | 2018 | 56 | 1.940 |
Why?
|
| Aging | 23 | 2018 | 1576 | 1.890 |
Why?
|
| Glial Cell Line-Derived Neurotrophic Factor | 15 | 2021 | 26 | 1.840 |
Why?
|
| Antiparkinson Agents | 6 | 2017 | 66 | 1.630 |
Why?
|
| Immunohistochemistry | 31 | 2022 | 364 | 1.560 |
Why?
|
| Mesencephalon | 10 | 2017 | 26 | 1.560 |
Why?
|
| Macaca mulatta | 30 | 2021 | 61 | 1.540 |
Why?
|
| Gene Transfer Techniques | 12 | 2021 | 29 | 1.450 |
Why?
|
| Cell- and Tissue-Based Therapy | 6 | 2021 | 13 | 1.360 |
Why?
|
| Male | 82 | 2025 | 15400 | 1.360 |
Why?
|
| Mice | 29 | 2022 | 1465 | 1.320 |
Why?
|
| Prodromal Symptoms | 2 | 2021 | 18 | 1.320 |
Why?
|
| Neurodegenerative Diseases | 7 | 2019 | 125 | 1.310 |
Why?
|
| Extracorporeal Shockwave Therapy | 2 | 2019 | 4 | 1.290 |
Why?
|
| Oligodendroglia | 3 | 2020 | 37 | 1.290 |
Why?
|
| Colon | 5 | 2018 | 143 | 1.280 |
Why?
|
| Dyskinesia, Drug-Induced | 4 | 2020 | 21 | 1.270 |
Why?
|
| Lewy Body Disease | 3 | 2025 | 100 | 1.240 |
Why?
|
| MPTP Poisoning | 4 | 2016 | 15 | 1.220 |
Why?
|
| Prions | 3 | 2019 | 8 | 1.190 |
Why?
|
| Female | 72 | 2025 | 15818 | 1.170 |
Why?
|
| Graft Survival | 8 | 2017 | 102 | 1.170 |
Why?
|
| Microglia | 8 | 2021 | 146 | 1.170 |
Why?
|
| Proto-Oncogene Proteins c-ret | 3 | 2021 | 6 | 1.160 |
Why?
|
| Rats, Sprague-Dawley | 19 | 2020 | 342 | 1.130 |
Why?
|
| Macaca fascicularis | 12 | 2021 | 25 | 1.120 |
Why?
|
| Cell Transplantation | 7 | 2013 | 23 | 1.080 |
Why?
|
| Stem Cell Transplantation | 7 | 2020 | 43 | 1.040 |
Why?
|
| Nerve Regeneration | 6 | 2009 | 14 | 1.020 |
Why?
|
| Primates | 6 | 2018 | 7 | 0.980 |
Why?
|
| Levodopa | 5 | 2020 | 47 | 0.980 |
Why?
|
| Enteric Nervous System | 2 | 2018 | 5 | 0.970 |
Why?
|
| Quinolinic Acid | 9 | 2019 | 11 | 0.920 |
Why?
|
| Aged | 37 | 2025 | 9334 | 0.920 |
Why?
|
| Stem Cells | 5 | 2020 | 41 | 0.910 |
Why?
|
| Aged, 80 and over | 23 | 2025 | 4894 | 0.890 |
Why?
|
| Alzheimer Disease | 11 | 2023 | 2144 | 0.860 |
Why?
|
| Axons | 3 | 2018 | 28 | 0.850 |
Why?
|
| Down-Regulation | 4 | 2014 | 102 | 0.840 |
Why?
|
| Cell Count | 14 | 2019 | 80 | 0.800 |
Why?
|
| Neurotoxins | 5 | 2007 | 16 | 0.800 |
Why?
|
| Parkinson Disease, Secondary | 4 | 2020 | 10 | 0.780 |
Why?
|
| Mutation | 8 | 2021 | 353 | 0.750 |
Why?
|
| Cisterna Magna | 1 | 2021 | 4 | 0.740 |
Why?
|
| Ribosomal Protein S6 | 1 | 2021 | 2 | 0.740 |
Why?
|
| DNA-Binding Proteins | 6 | 2023 | 274 | 0.730 |
Why?
|
| Gastrointestinal Diseases | 2 | 2018 | 36 | 0.730 |
Why?
|
| Cerebral Cortex | 9 | 2019 | 166 | 0.720 |
Why?
|
| Mitomycin | 1 | 2020 | 9 | 0.710 |
Why?
|
| Clinical Trials as Topic | 5 | 2016 | 239 | 0.710 |
Why?
|
| Middle Aged | 32 | 2025 | 9316 | 0.700 |
Why?
|
| Propionates | 7 | 2007 | 12 | 0.690 |
Why?
|
| Reproduction | 2 | 2016 | 10 | 0.680 |
Why?
|
| Motor Activity | 10 | 2020 | 332 | 0.670 |
Why?
|
| Neurosciences | 2 | 2009 | 9 | 0.650 |
Why?
|
| Homeodomain Proteins | 2 | 2019 | 61 | 0.650 |
Why?
|
| High-Intensity Focused Ultrasound Ablation | 1 | 2019 | 1 | 0.650 |
Why?
|
| Glial Cell Line-Derived Neurotrophic Factors | 2 | 2011 | 3 | 0.650 |
Why?
|
| Mice, Transgenic | 9 | 2022 | 227 | 0.640 |
Why?
|
| Estrogen Replacement Therapy | 4 | 2010 | 19 | 0.640 |
Why?
|
| Immunotherapy | 1 | 2019 | 56 | 0.640 |
Why?
|
| Blood-Brain Barrier | 1 | 2019 | 39 | 0.630 |
Why?
|
| Huntingtin Protein | 8 | 2019 | 12 | 0.630 |
Why?
|
| Estradiol | 3 | 2010 | 39 | 0.620 |
Why?
|
| Membrane Proteins | 2 | 2019 | 171 | 0.600 |
Why?
|
| Regeneration | 1 | 2018 | 21 | 0.600 |
Why?
|
| Antibodies | 2 | 2021 | 49 | 0.590 |
Why?
|
| Motor Skills Disorders | 1 | 2018 | 16 | 0.590 |
Why?
|
| Gastrointestinal Motility | 1 | 2018 | 11 | 0.590 |
Why?
|
| Transcription Factors | 4 | 2022 | 172 | 0.590 |
Why?
|
| Neurogenesis | 3 | 2017 | 8 | 0.580 |
Why?
|
| Central Nervous System Diseases | 1 | 2018 | 18 | 0.580 |
Why?
|
| Cryopreservation | 1 | 2017 | 17 | 0.560 |
Why?
|
| Axonal Transport | 3 | 2015 | 7 | 0.550 |
Why?
|
| tau Proteins | 5 | 2023 | 235 | 0.550 |
Why?
|
| Allografts | 2 | 2017 | 222 | 0.540 |
Why?
|
| Prion Diseases | 1 | 2016 | 2 | 0.540 |
Why?
|
| Cerebellum | 1 | 2016 | 47 | 0.530 |
Why?
|
| Transplants | 2 | 2016 | 10 | 0.520 |
Why?
|
| Protein Aggregates | 4 | 2019 | 9 | 0.520 |
Why?
|
| Amyotrophic Lateral Sclerosis | 1 | 2016 | 23 | 0.510 |
Why?
|
| Recovery of Function | 5 | 2020 | 300 | 0.500 |
Why?
|
| Congresses as Topic | 4 | 2017 | 31 | 0.490 |
Why?
|
| Gene Expression | 6 | 2020 | 204 | 0.470 |
Why?
|
| TDP-43 Proteinopathies | 1 | 2016 | 110 | 0.460 |
Why?
|
| Tissue Extracts | 1 | 2014 | 9 | 0.460 |
Why?
|
| Voltage-Dependent Anion Channel 1 | 1 | 2014 | 1 | 0.460 |
Why?
|
| Dopamine Plasma Membrane Transport Proteins | 4 | 2019 | 6 | 0.460 |
Why?
|
| Nuclear Receptor Subfamily 4, Group A, Member 2 | 4 | 2020 | 12 | 0.460 |
Why?
|
| Behavior, Animal | 11 | 2020 | 45 | 0.430 |
Why?
|
| Inflammation | 5 | 2020 | 288 | 0.430 |
Why?
|
| Inclusion Bodies | 4 | 2021 | 13 | 0.430 |
Why?
|
| Biomarkers | 8 | 2021 | 601 | 0.420 |
Why?
|
| Oxidopamine | 8 | 2023 | 10 | 0.420 |
Why?
|
| Neurosurgery | 1 | 2013 | 31 | 0.420 |
Why?
|
| Mice, Inbred C57BL | 12 | 2020 | 436 | 0.420 |
Why?
|
| Receptors, Nerve Growth Factor | 2 | 2003 | 9 | 0.410 |
Why?
|
| Stereotaxic Techniques | 4 | 2020 | 14 | 0.410 |
Why?
|
| Movement Disorders | 1 | 2013 | 91 | 0.410 |
Why?
|
| Melanins | 4 | 2020 | 7 | 0.410 |
Why?
|
| Dyneins | 1 | 2012 | 1 | 0.400 |
Why?
|
| Cytoplasmic Dyneins | 1 | 2012 | 1 | 0.400 |
Why?
|
| Promoter Regions, Genetic | 2 | 2015 | 99 | 0.400 |
Why?
|
| Brain-Derived Neurotrophic Factor | 4 | 2011 | 48 | 0.400 |
Why?
|
| Nitro Compounds | 7 | 2007 | 9 | 0.400 |
Why?
|
| Neuroglia | 4 | 2008 | 49 | 0.400 |
Why?
|
| Gene Expression Regulation | 9 | 2015 | 282 | 0.400 |
Why?
|
| Protein Folding | 3 | 2018 | 21 | 0.390 |
Why?
|
| Caudate Nucleus | 3 | 2016 | 11 | 0.380 |
Why?
|
| Cell Differentiation | 7 | 2020 | 135 | 0.380 |
Why?
|
| Disease Progression | 6 | 2019 | 722 | 0.370 |
Why?
|
| Treatment Outcome | 13 | 2020 | 3620 | 0.370 |
Why?
|
| Dentate Gyrus | 2 | 2010 | 6 | 0.360 |
Why?
|
| Myogenic Regulatory Factors | 1 | 2010 | 1 | 0.360 |
Why?
|
| MADS Domain Proteins | 1 | 2010 | 1 | 0.360 |
Why?
|
| Case-Control Studies | 6 | 2020 | 599 | 0.350 |
Why?
|
| Deep Brain Stimulation | 4 | 2018 | 39 | 0.350 |
Why?
|
| Prosencephalon | 3 | 2005 | 8 | 0.350 |
Why?
|
| Progesterone | 1 | 2010 | 11 | 0.340 |
Why?
|
| Protein Aggregation, Pathological | 3 | 2019 | 5 | 0.340 |
Why?
|
| Cysteine Proteinase Inhibitors | 2 | 2006 | 6 | 0.340 |
Why?
|
| Oligopeptides | 2 | 2006 | 24 | 0.330 |
Why?
|
| Transplantation | 1 | 2009 | 4 | 0.330 |
Why?
|
| Animal Rights | 1 | 2009 | 1 | 0.330 |
Why?
|
| Genetic Techniques | 1 | 2009 | 3 | 0.330 |
Why?
|
| Animal Experimentation | 1 | 2009 | 3 | 0.330 |
Why?
|
| Fetus | 1 | 2010 | 41 | 0.330 |
Why?
|
| Capsid | 1 | 2009 | 12 | 0.330 |
Why?
|
| Basal Ganglia | 1 | 2009 | 16 | 0.330 |
Why?
|
| Terrorism | 1 | 2009 | 14 | 0.330 |
Why?
|
| Hydrogels | 1 | 2009 | 7 | 0.330 |
Why?
|
| Cathepsin D | 1 | 2009 | 1 | 0.330 |
Why?
|
| HSC70 Heat-Shock Proteins | 1 | 2009 | 1 | 0.330 |
Why?
|
| Transplantation, Heterologous | 3 | 2014 | 20 | 0.330 |
Why?
|
| 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine | 6 | 2008 | 20 | 0.330 |
Why?
|
| History, 20th Century | 4 | 2017 | 47 | 0.330 |
Why?
|
| Proteasome Endopeptidase Complex | 1 | 2009 | 23 | 0.320 |
Why?
|
| Haplorhini | 5 | 2020 | 8 | 0.320 |
Why?
|
| Green Fluorescent Proteins | 5 | 2017 | 23 | 0.320 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2009 | 72 | 0.320 |
Why?
|
| Neuronal Plasticity | 1 | 2009 | 47 | 0.320 |
Why?
|
| Biomedical Research | 1 | 2009 | 66 | 0.310 |
Why?
|
| Neurofibrillary Tangles | 3 | 2023 | 194 | 0.310 |
Why?
|
| Central Nervous System | 3 | 2021 | 59 | 0.310 |
Why?
|
| Glial Fibrillary Acidic Protein | 4 | 2009 | 42 | 0.310 |
Why?
|
| Astrocytes | 5 | 2017 | 150 | 0.300 |
Why?
|
| Cholinergic Fibers | 3 | 2005 | 9 | 0.300 |
Why?
|
| Models, Animal | 4 | 2021 | 120 | 0.300 |
Why?
|
| Receptor, Nerve Growth Factor | 3 | 2003 | 9 | 0.300 |
Why?
|
| Rats, Inbred F344 | 7 | 2020 | 35 | 0.300 |
Why?
|
| Societies, Scientific | 1 | 2008 | 9 | 0.300 |
Why?
|
| Amyloid beta-Peptides | 3 | 2023 | 327 | 0.290 |
Why?
|
| Adrenal Medulla | 1 | 2007 | 7 | 0.290 |
Why?
|
| Time Factors | 8 | 2013 | 1501 | 0.280 |
Why?
|
| Autopsy | 6 | 2018 | 346 | 0.280 |
Why?
|
| Transplantation, Autologous | 1 | 2007 | 170 | 0.280 |
Why?
|
| Supranuclear Palsy, Progressive | 2 | 2007 | 28 | 0.270 |
Why?
|
| Colon, Sigmoid | 2 | 2017 | 17 | 0.270 |
Why?
|
| Oxidative Stress | 3 | 2011 | 107 | 0.270 |
Why?
|
| Tissue Distribution | 3 | 2021 | 33 | 0.270 |
Why?
|
| Choroid Plexus | 1 | 2006 | 7 | 0.270 |
Why?
|
| Hippocampus | 6 | 2013 | 284 | 0.260 |
Why?
|
| Nuclear Proteins | 6 | 2014 | 88 | 0.260 |
Why?
|
| Functional Laterality | 5 | 2010 | 68 | 0.260 |
Why?
|
| Cell Death | 4 | 2007 | 46 | 0.260 |
Why?
|
| Chemokine CCL5 | 2 | 2016 | 14 | 0.250 |
Why?
|
| Tomography, Emission-Computed, Single-Photon | 2 | 2019 | 80 | 0.250 |
Why?
|
| History, 21st Century | 3 | 2017 | 24 | 0.250 |
Why?
|
| Transduction, Genetic | 3 | 2021 | 15 | 0.240 |
Why?
|
| Cell Survival | 6 | 2011 | 120 | 0.230 |
Why?
|
| Proteomics | 1 | 2025 | 93 | 0.230 |
Why?
|
| Rats, Inbred Lew | 4 | 2020 | 11 | 0.230 |
Why?
|
| Peptides | 3 | 2015 | 106 | 0.230 |
Why?
|
| Basal Nucleus of Meynert | 2 | 2014 | 10 | 0.220 |
Why?
|
| Cell Proliferation | 2 | 2020 | 178 | 0.220 |
Why?
|
| RNA Interference | 2 | 2015 | 36 | 0.220 |
Why?
|
| Rotenone | 2 | 2018 | 10 | 0.220 |
Why?
|
| Adult | 12 | 2018 | 8168 | 0.220 |
Why?
|
| Hypokinesia | 1 | 2023 | 23 | 0.220 |
Why?
|
| Fluorescent Antibody Technique | 4 | 2021 | 58 | 0.210 |
Why?
|
| Endopeptidase K | 2 | 2017 | 2 | 0.210 |
Why?
|
| Cell Line | 4 | 2019 | 280 | 0.210 |
Why?
|
| Positron-Emission Tomography | 4 | 2014 | 90 | 0.210 |
Why?
|
| Ciliary Neurotrophic Factor | 3 | 2011 | 8 | 0.210 |
Why?
|
| Sympatholytics | 4 | 2011 | 7 | 0.210 |
Why?
|
| Brain Injuries | 1 | 2003 | 36 | 0.210 |
Why?
|
| Ubiquitin-Protein Ligases | 1 | 2002 | 30 | 0.200 |
Why?
|
| Densitometry | 2 | 2021 | 9 | 0.200 |
Why?
|
| Frontotemporal Dementia | 1 | 2022 | 13 | 0.200 |
Why?
|
| Tauopathies | 1 | 2022 | 21 | 0.200 |
Why?
|
| Signal Transduction | 3 | 2021 | 447 | 0.200 |
Why?
|
| Animals, Genetically Modified | 2 | 2021 | 20 | 0.200 |
Why?
|
| beta-Globins | 1 | 2022 | 3 | 0.200 |
Why?
|
| Acetylcholine | 1 | 2002 | 7 | 0.200 |
Why?
|
| Viruses | 1 | 2002 | 6 | 0.200 |
Why?
|
| Recombinant Proteins | 2 | 2019 | 216 | 0.190 |
Why?
|
| Rats, Transgenic | 2 | 2012 | 19 | 0.190 |
Why?
|
| Epigenesis, Genetic | 2 | 2020 | 86 | 0.190 |
Why?
|
| Toll-Like Receptor 4 | 2 | 2018 | 33 | 0.190 |
Why?
|
| Choline O-Acetyltransferase | 4 | 2006 | 21 | 0.190 |
Why?
|
| Coloring Agents | 1 | 2021 | 14 | 0.190 |
Why?
|
| Drug Delivery Systems | 2 | 2019 | 31 | 0.180 |
Why?
|
| Autophagy | 2 | 2022 | 30 | 0.180 |
Why?
|
| Cognition Disorders | 4 | 2019 | 1019 | 0.180 |
Why?
|
| Microscopy, Confocal | 3 | 2015 | 93 | 0.180 |
Why?
|
| Severity of Illness Index | 5 | 2015 | 990 | 0.180 |
Why?
|
| Oligonucleotides, Antisense | 1 | 2020 | 12 | 0.180 |
Why?
|
| Ovariectomy | 4 | 2010 | 26 | 0.170 |
Why?
|
| Magnetic Resonance Imaging | 4 | 2019 | 1194 | 0.170 |
Why?
|
| Nerve Growth Factor | 2 | 2014 | 38 | 0.170 |
Why?
|
| Radiopharmaceuticals | 2 | 2012 | 54 | 0.170 |
Why?
|
| Microinjections | 1 | 2019 | 4 | 0.170 |
Why?
|
| Adenoviridae | 2 | 2011 | 17 | 0.170 |
Why?
|
| Treatment Failure | 1 | 2020 | 163 | 0.170 |
Why?
|
| NF-kappa B | 2 | 2012 | 118 | 0.170 |
Why?
|
| Ubiquitin | 3 | 2009 | 31 | 0.170 |
Why?
|
| Biopolymers | 1 | 2019 | 6 | 0.160 |
Why?
|
| Interneurons | 1 | 2019 | 5 | 0.160 |
Why?
|
| T-Lymphocytes | 1 | 2020 | 97 | 0.160 |
Why?
|
| Protein Transport | 1 | 2019 | 32 | 0.160 |
Why?
|
| Macrophage Activation | 1 | 2019 | 11 | 0.160 |
Why?
|
| Gene-Environment Interaction | 1 | 2019 | 18 | 0.160 |
Why?
|
| Organ Specificity | 1 | 2019 | 42 | 0.160 |
Why?
|
| Models, Neurological | 1 | 2019 | 25 | 0.160 |
Why?
|
| Chemokine CCL11 | 2 | 2016 | 9 | 0.160 |
Why?
|
| Amyloid | 1 | 2019 | 57 | 0.160 |
Why?
|
| GABAergic Neurons | 1 | 2019 | 4 | 0.160 |
Why?
|
| Nanostructures | 1 | 2019 | 10 | 0.160 |
Why?
|
| Gastrointestinal Microbiome | 2 | 2018 | 181 | 0.160 |
Why?
|
| Mitochondria | 2 | 2016 | 71 | 0.160 |
Why?
|
| Dyskinesias | 3 | 2009 | 21 | 0.150 |
Why?
|
| Frontal Lobe | 3 | 2004 | 83 | 0.150 |
Why?
|
| Age Factors | 6 | 2009 | 788 | 0.150 |
Why?
|
| Prenatal Exposure Delayed Effects | 2 | 2011 | 7 | 0.150 |
Why?
|
| Tissue Fixation | 1 | 2018 | 7 | 0.150 |
Why?
|
| Psychosine | 1 | 2018 | 1 | 0.150 |
Why?
|
| Galactosylceramidase | 1 | 2018 | 2 | 0.150 |
Why?
|
| Formaldehyde | 1 | 2018 | 9 | 0.150 |
Why?
|
| Cell Engineering | 1 | 2018 | 1 | 0.150 |
Why?
|
| Drug Administration Schedule | 3 | 2010 | 166 | 0.150 |
Why?
|
| Polymerase Chain Reaction | 1 | 2018 | 120 | 0.150 |
Why?
|
| Injections | 3 | 2019 | 45 | 0.140 |
Why?
|
| Microfilament Proteins | 3 | 2015 | 25 | 0.140 |
Why?
|
| CD8-Positive T-Lymphocytes | 2 | 2016 | 113 | 0.140 |
Why?
|
| Dihydroxyphenylalanine | 2 | 2010 | 4 | 0.140 |
Why?
|
| Lentivirus | 3 | 2009 | 11 | 0.140 |
Why?
|
| HEK293 Cells | 1 | 2017 | 67 | 0.140 |
Why?
|
| Pyruvic Acid | 1 | 2016 | 1 | 0.140 |
Why?
|
| Cells, Cultured | 4 | 2018 | 539 | 0.140 |
Why?
|
| Cytoprotection | 2 | 2007 | 9 | 0.140 |
Why?
|
| G Protein-Coupled Inwardly-Rectifying Potassium Channels | 1 | 2016 | 1 | 0.140 |
Why?
|
| Calbindins | 1 | 2016 | 2 | 0.140 |
Why?
|
| Psychomotor Performance | 3 | 2009 | 213 | 0.130 |
Why?
|
| Mice, Knockout | 3 | 2018 | 316 | 0.130 |
Why?
|
| Permeability | 2 | 2013 | 120 | 0.130 |
Why?
|
| Analysis of Variance | 5 | 2010 | 276 | 0.130 |
Why?
|
| Pyridines | 2 | 2016 | 37 | 0.130 |
Why?
|
| Environment | 2 | 2009 | 47 | 0.130 |
Why?
|
| Ataxin-1 | 1 | 2015 | 1 | 0.130 |
Why?
|
| Cerebellar Nuclei | 1 | 2015 | 1 | 0.130 |
Why?
|
| Spinocerebellar Ataxias | 1 | 2015 | 1 | 0.130 |
Why?
|
| Gastrointestinal Tract | 1 | 2016 | 53 | 0.130 |
Why?
|
| Adrenergic Uptake Inhibitors | 2 | 2012 | 6 | 0.120 |
Why?
|
| Tyrosine | 2 | 2011 | 25 | 0.120 |
Why?
|
| Heterografts | 1 | 2014 | 16 | 0.110 |
Why?
|
| Immune Tolerance | 1 | 2014 | 15 | 0.110 |
Why?
|
| Neural Stem Cells | 1 | 2014 | 13 | 0.110 |
Why?
|
| Dendrites | 2 | 2004 | 10 | 0.110 |
Why?
|
| DNA Methylation | 1 | 2015 | 165 | 0.110 |
Why?
|
| Polysaccharides | 1 | 2013 | 12 | 0.110 |
Why?
|
| Chromatography, Gas | 1 | 2013 | 10 | 0.110 |
Why?
|
| Pregnancy | 3 | 2011 | 341 | 0.110 |
Why?
|
| Vagus Nerve | 1 | 2013 | 14 | 0.110 |
Why?
|
| Gastrointestinal Agents | 1 | 2013 | 12 | 0.110 |
Why?
|
| Response Elements | 1 | 2013 | 15 | 0.110 |
Why?
|
| Graft Rejection | 1 | 2014 | 71 | 0.110 |
Why?
|
| Receptors, N-Methyl-D-Aspartate | 1 | 2013 | 26 | 0.110 |
Why?
|
| Cyclic AMP Response Element-Binding Protein | 1 | 2013 | 41 | 0.110 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 3 | 2009 | 28 | 0.110 |
Why?
|
| Receptor, Adenosine A2A | 1 | 2013 | 2 | 0.110 |
Why?
|
| Heterocyclic Compounds, 3-Ring | 1 | 2013 | 13 | 0.100 |
Why?
|
| Protein Engineering | 1 | 2013 | 7 | 0.100 |
Why?
|
| Swine | 2 | 2019 | 82 | 0.100 |
Why?
|
| Linear Models | 1 | 2013 | 255 | 0.100 |
Why?
|
| Norepinephrine Plasma Membrane Transport Proteins | 1 | 2012 | 2 | 0.100 |
Why?
|
| Transgenes | 2 | 2013 | 14 | 0.100 |
Why?
|
| National Institutes of Health (U.S.) | 1 | 2013 | 25 | 0.100 |
Why?
|
| Morpholines | 1 | 2012 | 12 | 0.100 |
Why?
|
| Carrier Proteins | 3 | 2011 | 106 | 0.100 |
Why?
|
| tat Gene Products, Human Immunodeficiency Virus | 1 | 2012 | 11 | 0.100 |
Why?
|
| Neurobiology | 1 | 2012 | 6 | 0.100 |
Why?
|
| Neurites | 1 | 2012 | 9 | 0.100 |
Why?
|
| Substance P | 1 | 2012 | 12 | 0.100 |
Why?
|
| PPAR alpha | 1 | 2013 | 62 | 0.100 |
Why?
|
| Calcium Channels, L-Type | 1 | 2012 | 54 | 0.100 |
Why?
|
| Pyrazoles | 1 | 2013 | 58 | 0.100 |
Why?
|
| Endotoxins | 1 | 2011 | 20 | 0.100 |
Why?
|
| N-Methyl-3,4-methylenedioxyamphetamine | 1 | 2011 | 1 | 0.100 |
Why?
|
| Adrenergic Neurons | 1 | 2011 | 1 | 0.100 |
Why?
|
| Embryonic Stem Cells | 1 | 2011 | 11 | 0.100 |
Why?
|
| Neurotoxicity Syndromes | 1 | 2011 | 3 | 0.100 |
Why?
|
| Neural Pathways | 2 | 2015 | 73 | 0.100 |
Why?
|
| Biopsy | 3 | 2017 | 220 | 0.100 |
Why?
|
| Synaptic Transmission | 2 | 2020 | 25 | 0.090 |
Why?
|
| Neuropeptides | 2 | 2008 | 30 | 0.090 |
Why?
|
| Exploratory Behavior | 2 | 2019 | 10 | 0.090 |
Why?
|
| Microtubule-Associated Proteins | 2 | 2008 | 20 | 0.090 |
Why?
|
| Phenotype | 2 | 2002 | 312 | 0.090 |
Why?
|
| Intestines | 1 | 2011 | 100 | 0.090 |
Why?
|
| MEF2 Transcription Factors | 1 | 2010 | 2 | 0.090 |
Why?
|
| Aspartic Acid Endopeptidases | 1 | 2010 | 5 | 0.090 |
Why?
|
| Cytokines | 2 | 2015 | 231 | 0.090 |
Why?
|
| Blood Vessels | 1 | 2010 | 14 | 0.090 |
Why?
|
| Amyloid Precursor Protein Secretases | 1 | 2010 | 11 | 0.090 |
Why?
|
| HIV-1 | 1 | 2012 | 236 | 0.090 |
Why?
|
| Enzyme Therapy | 1 | 2010 | 1 | 0.090 |
Why?
|
| Isotope Labeling | 1 | 2010 | 3 | 0.090 |
Why?
|
| Enzymes | 1 | 2010 | 5 | 0.090 |
Why?
|
| Animals, Newborn | 4 | 2014 | 46 | 0.090 |
Why?
|
| Fluorine Radioisotopes | 1 | 2010 | 5 | 0.090 |
Why?
|
| Clinical Trials, Phase II as Topic | 1 | 2010 | 21 | 0.080 |
Why?
|
| Fluorodeoxyglucose F18 | 2 | 2007 | 38 | 0.080 |
Why?
|
| Glutamic Acid | 1 | 2010 | 25 | 0.080 |
Why?
|
| Phosphopyruvate Hydratase | 1 | 2009 | 12 | 0.080 |
Why?
|
| Plasmids | 1 | 2009 | 47 | 0.080 |
Why?
|
| Presynaptic Terminals | 2 | 2010 | 11 | 0.080 |
Why?
|
| Vesicular Monoamine Transport Proteins | 1 | 2008 | 2 | 0.080 |
Why?
|
| Rotarod Performance Test | 1 | 2008 | 8 | 0.080 |
Why?
|
| Double-Blind Method | 4 | 2015 | 433 | 0.080 |
Why?
|
| Gene Expression Regulation, Developmental | 1 | 2008 | 37 | 0.080 |
Why?
|
| Reference Values | 2 | 2007 | 201 | 0.080 |
Why?
|
| gamma-Aminobutyric Acid | 1 | 2008 | 28 | 0.080 |
Why?
|
| Random Allocation | 1 | 2008 | 130 | 0.080 |
Why?
|
| Neuropsychological Tests | 4 | 2014 | 1253 | 0.080 |
Why?
|
| Transcription, Genetic | 2 | 2013 | 107 | 0.080 |
Why?
|
| Adolescent | 2 | 2006 | 2319 | 0.080 |
Why?
|
| Anterior Thalamic Nuclei | 1 | 2008 | 3 | 0.070 |
Why?
|
| RNA, Messenger | 2 | 2009 | 309 | 0.070 |
Why?
|
| Gliosis | 2 | 2009 | 6 | 0.070 |
Why?
|
| Hypothalamic Area, Lateral | 1 | 2007 | 2 | 0.070 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 2 | 2009 | 97 | 0.070 |
Why?
|
| Chromogranin A | 1 | 2007 | 10 | 0.070 |
Why?
|
| Phosphorylation | 2 | 2023 | 149 | 0.070 |
Why?
|
| Lipofuscin | 1 | 2007 | 1 | 0.070 |
Why?
|
| Intranuclear Inclusion Bodies | 1 | 2007 | 2 | 0.070 |
Why?
|
| Risk Factors | 2 | 2011 | 2412 | 0.070 |
Why?
|
| Epilepsy | 1 | 2008 | 65 | 0.070 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 2007 | 14 | 0.070 |
Why?
|
| Organisms, Genetically Modified | 1 | 2007 | 1 | 0.070 |
Why?
|
| Longitudinal Studies | 2 | 2009 | 1395 | 0.070 |
Why?
|
| Immunoblotting | 1 | 2006 | 57 | 0.070 |
Why?
|
| Maze Learning | 2 | 2019 | 16 | 0.070 |
Why?
|
| Lameness, Animal | 1 | 2006 | 5 | 0.070 |
Why?
|
| Glial Cell Line-Derived Neurotrophic Factor Receptors | 1 | 2006 | 2 | 0.070 |
Why?
|
| Plaque, Amyloid | 2 | 2010 | 146 | 0.070 |
Why?
|
| Locomotion | 1 | 2006 | 24 | 0.070 |
Why?
|
| Synucleins | 2 | 2003 | 7 | 0.070 |
Why?
|
| United States | 1 | 2013 | 2197 | 0.070 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2009 | 352 | 0.070 |
Why?
|
| Receptors, GABA-A | 1 | 2006 | 3 | 0.060 |
Why?
|
| Fungicides, Industrial | 1 | 2006 | 1 | 0.060 |
Why?
|
| Herbicides | 1 | 2006 | 1 | 0.060 |
Why?
|
| Maneb | 1 | 2006 | 1 | 0.060 |
Why?
|
| Pesticides | 1 | 2006 | 1 | 0.060 |
Why?
|
| Paraquat | 1 | 2006 | 2 | 0.060 |
Why?
|
| Matched-Pair Analysis | 1 | 2006 | 30 | 0.060 |
Why?
|
| Bromodeoxyuridine | 1 | 2004 | 10 | 0.060 |
Why?
|
| Nucleic Acid Amplification Techniques | 1 | 2004 | 6 | 0.060 |
Why?
|
| Motor Skills | 2 | 2003 | 53 | 0.060 |
Why?
|
| Cytoskeleton | 1 | 2004 | 38 | 0.060 |
Why?
|
| Obesity | 1 | 2007 | 321 | 0.060 |
Why?
|
| Gait Disorders, Neurologic | 1 | 2006 | 138 | 0.060 |
Why?
|
| 3,4-Methylenedioxyamphetamine | 1 | 2003 | 1 | 0.060 |
Why?
|
| Biogenic Monoamines | 1 | 2003 | 1 | 0.060 |
Why?
|
| Hallucinogens | 1 | 2003 | 2 | 0.060 |
Why?
|
| Estrogens | 1 | 2003 | 24 | 0.050 |
Why?
|
| Movement | 1 | 2004 | 118 | 0.050 |
Why?
|
| Dopamine and cAMP-Regulated Phosphoprotein 32 | 1 | 2003 | 2 | 0.050 |
Why?
|
| Leukocyte Common Antigens | 1 | 2003 | 6 | 0.050 |
Why?
|
| Luminescent Proteins | 1 | 2003 | 7 | 0.050 |
Why?
|
| Phosphoproteins | 1 | 2003 | 28 | 0.050 |
Why?
|
| Nitrobenzenes | 1 | 2003 | 1 | 0.050 |
Why?
|
| Cyclooxygenase Inhibitors | 1 | 2003 | 27 | 0.050 |
Why?
|
| Membrane Transport Proteins | 1 | 2003 | 57 | 0.050 |
Why?
|
| Isoenzymes | 1 | 2003 | 53 | 0.050 |
Why?
|
| Infarction, Middle Cerebral Artery | 1 | 2003 | 13 | 0.050 |
Why?
|
| Papio | 2 | 2013 | 7 | 0.050 |
Why?
|
| Immunophilins | 1 | 2002 | 1 | 0.050 |
Why?
|
| Sulfonamides | 1 | 2003 | 41 | 0.050 |
Why?
|
| Pyrrolidines | 1 | 2002 | 11 | 0.050 |
Why?
|
| Aspartic Acid | 1 | 2003 | 14 | 0.050 |
Why?
|
| Mice, Inbred NOD | 2 | 2014 | 30 | 0.050 |
Why?
|
| Thiolester Hydrolases | 1 | 2002 | 3 | 0.050 |
Why?
|
| Magnetic Resonance Spectroscopy | 1 | 2003 | 42 | 0.050 |
Why?
|
| Mice, SCID | 2 | 2014 | 45 | 0.050 |
Why?
|
| Neurologic Examination | 1 | 2003 | 115 | 0.050 |
Why?
|
| Ubiquitin Thiolesterase | 1 | 2002 | 4 | 0.050 |
Why?
|
| Ligases | 1 | 2002 | 10 | 0.050 |
Why?
|
| Stroke | 1 | 2006 | 275 | 0.050 |
Why?
|
| Energy Metabolism | 1 | 2003 | 55 | 0.050 |
Why?
|
| Basic Helix-Loop-Helix Leucine Zipper Transcription Factors | 1 | 2022 | 15 | 0.050 |
Why?
|
| Prefrontal Cortex | 1 | 2004 | 149 | 0.050 |
Why?
|
| Dopamine Agents | 1 | 2002 | 16 | 0.050 |
Why?
|
| Lysosomes | 1 | 2022 | 26 | 0.050 |
Why?
|
| Antigens, CD | 2 | 2015 | 52 | 0.050 |
Why?
|
| Binding, Competitive | 1 | 2002 | 24 | 0.050 |
Why?
|
| Microscopy, Fluorescence | 1 | 2002 | 79 | 0.050 |
Why?
|
| Cebus | 1 | 2002 | 1 | 0.050 |
Why?
|
| Injections, Intramuscular | 1 | 2002 | 7 | 0.050 |
Why?
|
| Causality | 1 | 2002 | 56 | 0.050 |
Why?
|
| Problem Solving | 1 | 2002 | 47 | 0.050 |
Why?
|
| Staining and Labeling | 1 | 2021 | 16 | 0.050 |
Why?
|
| Reproducibility of Results | 1 | 2003 | 735 | 0.050 |
Why?
|
| Entorhinal Cortex | 1 | 2021 | 40 | 0.050 |
Why?
|
| Brain Stem | 2 | 2015 | 19 | 0.050 |
Why?
|
| Brain Mapping | 1 | 2002 | 167 | 0.040 |
Why?
|
| Genotype | 1 | 2002 | 359 | 0.040 |
Why?
|
| Rats, Nude | 1 | 2020 | 4 | 0.040 |
Why?
|
| Models, Theoretical | 1 | 2020 | 84 | 0.040 |
Why?
|
| Autografts | 1 | 2020 | 31 | 0.040 |
Why?
|
| Feasibility Studies | 2 | 2014 | 233 | 0.040 |
Why?
|
| Synaptophysin | 2 | 2009 | 9 | 0.040 |
Why?
|
| LLC-PK1 Cells | 1 | 2019 | 1 | 0.040 |
Why?
|
| Child | 2 | 2017 | 1423 | 0.040 |
Why?
|
| Injections, Intraventricular | 1 | 2019 | 8 | 0.040 |
Why?
|
| Neuroblastoma | 1 | 2019 | 19 | 0.040 |
Why?
|
| Exons | 1 | 2019 | 33 | 0.040 |
Why?
|
| Ventral Tegmental Area | 1 | 2019 | 9 | 0.040 |
Why?
|
| CD3 Complex | 1 | 2018 | 5 | 0.040 |
Why?
|
| Gene Knockdown Techniques | 1 | 2019 | 45 | 0.040 |
Why?
|
| Monocytes | 1 | 2019 | 64 | 0.040 |
Why?
|
| Amygdala | 1 | 2019 | 43 | 0.040 |
Why?
|
| Dysbiosis | 1 | 2018 | 56 | 0.040 |
Why?
|
| Cell Line, Tumor | 1 | 2019 | 249 | 0.040 |
Why?
|
| Statistics, Nonparametric | 2 | 2010 | 130 | 0.040 |
Why?
|
| Eating | 2 | 2009 | 59 | 0.040 |
Why?
|
| Anniversaries and Special Events | 1 | 2017 | 3 | 0.040 |
Why?
|
| Anxiety | 1 | 2019 | 161 | 0.040 |
Why?
|
| History, 19th Century | 1 | 2017 | 29 | 0.040 |
Why?
|
| Submandibular Gland | 1 | 2017 | 1 | 0.030 |
Why?
|
| Zonula Occludens-1 Protein | 1 | 2017 | 16 | 0.030 |
Why?
|
| 1-Methyl-4-phenylpyridinium | 1 | 2016 | 1 | 0.030 |
Why?
|
| Caenorhabditis elegans | 1 | 2016 | 6 | 0.030 |
Why?
|
| Brain Chemistry | 2 | 2010 | 44 | 0.030 |
Why?
|
| Thiazolidinediones | 1 | 2016 | 9 | 0.030 |
Why?
|
| Oxygen Consumption | 1 | 2016 | 51 | 0.030 |
Why?
|
| Feces | 1 | 2017 | 107 | 0.030 |
Why?
|
| Antibodies, Blocking | 1 | 2016 | 6 | 0.030 |
Why?
|
| Adaptive Immunity | 1 | 2016 | 18 | 0.030 |
Why?
|
| Heterozygote | 1 | 2016 | 102 | 0.030 |
Why?
|
| Body Weight | 2 | 2009 | 146 | 0.030 |
Why?
|
| Skin | 1 | 2017 | 115 | 0.030 |
Why?
|
| Purkinje Cells | 1 | 2015 | 2 | 0.030 |
Why?
|
| Thalamus | 1 | 2015 | 16 | 0.030 |
Why?
|
| Palmitic Acid | 1 | 2015 | 4 | 0.030 |
Why?
|
| Inflammation Mediators | 1 | 2016 | 68 | 0.030 |
Why?
|
| Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha | 1 | 2015 | 9 | 0.030 |
Why?
|
| Serotonin Plasma Membrane Transport Proteins | 1 | 2015 | 13 | 0.030 |
Why?
|
| Genes, Reporter | 1 | 2015 | 24 | 0.030 |
Why?
|
| Mental Disorders | 1 | 2018 | 181 | 0.030 |
Why?
|
| Oligodendrocyte Transcription Factor 2 | 1 | 2015 | 2 | 0.030 |
Why?
|
| Basic Helix-Loop-Helix Transcription Factors | 1 | 2015 | 6 | 0.030 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2016 | 116 | 0.030 |
Why?
|
| CCAAT-Binding Factor | 1 | 2015 | 2 | 0.030 |
Why?
|
| Calcium-Binding Proteins | 1 | 2015 | 25 | 0.030 |
Why?
|
| Societies, Medical | 1 | 2016 | 154 | 0.030 |
Why?
|
| Animals, Outbred Strains | 1 | 2014 | 1 | 0.030 |
Why?
|
| Up-Regulation | 1 | 2015 | 177 | 0.030 |
Why?
|
| Synapses | 1 | 2013 | 36 | 0.030 |
Why?
|
| Protein Binding | 1 | 2013 | 133 | 0.030 |
Why?
|
| Radioactive Tracers | 1 | 2013 | 1 | 0.030 |
Why?
|
| Atomoxetine Hydrochloride | 1 | 2012 | 1 | 0.030 |
Why?
|
| Propylamines | 1 | 2012 | 1 | 0.030 |
Why?
|
| I-kappa B Kinase | 1 | 2012 | 6 | 0.030 |
Why?
|
| Kinetics | 1 | 2012 | 194 | 0.030 |
Why?
|
| Neurosurgical Procedures | 1 | 2014 | 128 | 0.020 |
Why?
|
| Cohort Studies | 1 | 2018 | 1940 | 0.020 |
Why?
|
| Amino Acid Sequence | 1 | 2012 | 161 | 0.020 |
Why?
|
| Molecular Sequence Data | 1 | 2012 | 200 | 0.020 |
Why?
|
| Acute-Phase Proteins | 1 | 2011 | 13 | 0.020 |
Why?
|
| Sucrose | 1 | 2011 | 18 | 0.020 |
Why?
|
| Immunoenzyme Techniques | 1 | 2011 | 32 | 0.020 |
Why?
|
| Escherichia coli Infections | 1 | 2011 | 26 | 0.020 |
Why?
|
| Follow-Up Studies | 2 | 2010 | 1863 | 0.020 |
Why?
|
| Microscopy | 1 | 2011 | 10 | 0.020 |
Why?
|
| Escherichia coli | 1 | 2011 | 56 | 0.020 |
Why?
|
| Memory | 1 | 2013 | 311 | 0.020 |
Why?
|
| Nerve Fibers, Myelinated | 1 | 2011 | 29 | 0.020 |
Why?
|
| Gene Targeting | 1 | 2011 | 10 | 0.020 |
Why?
|
| Gene Dosage | 1 | 2011 | 18 | 0.020 |
Why?
|
| Membrane Glycoproteins | 1 | 2011 | 72 | 0.020 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2012 | 192 | 0.020 |
Why?
|
| Weight Gain | 1 | 2011 | 66 | 0.020 |
Why?
|
| Electron Transport Complex IV | 1 | 2010 | 2 | 0.020 |
Why?
|
| Silver Staining | 1 | 2010 | 4 | 0.020 |
Why?
|
| NADPH Dehydrogenase | 1 | 2010 | 6 | 0.020 |
Why?
|
| Molecular Weight | 1 | 2010 | 29 | 0.020 |
Why?
|
| Models, Biological | 1 | 2012 | 329 | 0.020 |
Why?
|
| Postmortem Changes | 1 | 2010 | 31 | 0.020 |
Why?
|
| Weight Loss | 1 | 2011 | 130 | 0.020 |
Why?
|
| Calcium | 1 | 2013 | 381 | 0.020 |
Why?
|
| Intestinal Mucosa | 1 | 2011 | 192 | 0.020 |
Why?
|
| In Situ Hybridization | 1 | 2009 | 49 | 0.020 |
Why?
|
| Diet | 1 | 2011 | 220 | 0.020 |
Why?
|
| CD8 Antigens | 1 | 2009 | 11 | 0.020 |
Why?
|
| Microscopy, Electron | 1 | 2009 | 67 | 0.020 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2009 | 139 | 0.020 |
Why?
|
| CD4 Antigens | 1 | 2009 | 29 | 0.020 |
Why?
|
| Viral Matrix Proteins | 1 | 2009 | 3 | 0.020 |
Why?
|
| Oleanolic Acid | 1 | 2009 | 6 | 0.020 |
Why?
|
| Antigens, Differentiation, Myelomonocytic | 1 | 2009 | 5 | 0.020 |
Why?
|
| Calcitonin Gene-Related Peptide | 1 | 2009 | 12 | 0.020 |
Why?
|
| Nitric Oxide Synthase Type I | 1 | 2008 | 5 | 0.020 |
Why?
|
| NADP | 1 | 2008 | 9 | 0.020 |
Why?
|
| Videotape Recording | 1 | 2009 | 29 | 0.020 |
Why?
|
| Neocortex | 1 | 2009 | 32 | 0.020 |
Why?
|
| Cats | 1 | 2008 | 30 | 0.020 |
Why?
|
| HLA-DR Antigens | 1 | 2008 | 11 | 0.020 |
Why?
|
| Spinal Cord | 1 | 2009 | 85 | 0.020 |
Why?
|
| Risk Assessment | 1 | 2011 | 677 | 0.020 |
Why?
|
| Predictive Value of Tests | 1 | 2009 | 496 | 0.020 |
Why?
|
| Microelectrodes | 1 | 2008 | 18 | 0.020 |
Why?
|
| Drinking | 1 | 2007 | 5 | 0.020 |
Why?
|
| Binding Sites | 1 | 2007 | 75 | 0.020 |
Why?
|
| Nerve Fibers | 1 | 2007 | 12 | 0.020 |
Why?
|
| Syndecan-3 | 1 | 2007 | 1 | 0.020 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 1 | 2007 | 6 | 0.020 |
Why?
|
| Macaca | 1 | 2006 | 2 | 0.020 |
Why?
|
| Flow Cytometry | 1 | 2006 | 116 | 0.020 |
Why?
|
| Protein Subunits | 1 | 2006 | 19 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-fos | 1 | 2005 | 6 | 0.020 |
Why?
|
| Histological Techniques | 1 | 2005 | 6 | 0.020 |
Why?
|
| Fibroblasts | 1 | 2005 | 59 | 0.020 |
Why?
|
| Dynamins | 1 | 2004 | 4 | 0.010 |
Why?
|
| Tubulin | 1 | 2004 | 17 | 0.010 |
Why?
|
| Neurofilament Proteins | 1 | 2004 | 17 | 0.010 |
Why?
|
| Age of Onset | 1 | 2004 | 99 | 0.010 |
Why?
|
| Pyramidal Cells | 1 | 2004 | 34 | 0.010 |
Why?
|
| Adaptor Proteins, Vesicular Transport | 1 | 2004 | 42 | 0.010 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2004 | 65 | 0.010 |
Why?
|
| Estrous Cycle | 1 | 2003 | 1 | 0.010 |
Why?
|
| Homovanillic Acid | 1 | 2003 | 1 | 0.010 |
Why?
|
| 3,4-Dihydroxyphenylacetic Acid | 1 | 2003 | 3 | 0.010 |
Why?
|
| Body Constitution | 1 | 2003 | 3 | 0.010 |
Why?
|
| Tomography, Emission-Computed | 1 | 2003 | 9 | 0.010 |
Why?
|
| Postmenopause | 1 | 2003 | 52 | 0.010 |
Why?
|
| Nucleus Accumbens | 1 | 2003 | 14 | 0.010 |
Why?
|
| Body Temperature | 1 | 2003 | 50 | 0.010 |
Why?
|
| Cyclooxygenase 1 | 1 | 2003 | 6 | 0.010 |
Why?
|
| Prostaglandin-Endoperoxide Synthases | 1 | 2003 | 25 | 0.010 |
Why?
|
| Cyclooxygenase 2 | 1 | 2003 | 28 | 0.010 |
Why?
|
| Cyclooxygenase 2 Inhibitors | 1 | 2003 | 23 | 0.010 |
Why?
|
| Ligands | 1 | 2002 | 41 | 0.010 |
Why?
|
| Sex Characteristics | 1 | 2003 | 121 | 0.010 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2003 | 111 | 0.010 |
Why?
|
| Parietal Lobe | 1 | 2002 | 18 | 0.010 |
Why?
|
| Brain Ischemia | 1 | 2003 | 63 | 0.010 |
Why?
|
| Temporal Lobe | 1 | 2002 | 87 | 0.010 |
Why?
|
| Chronic Disease | 1 | 2003 | 442 | 0.010 |
Why?
|
| Radiography | 1 | 2003 | 651 | 0.010 |
Why?
|
| Dementia | 1 | 2006 | 579 | 0.010 |
Why?
|
| Cognition | 1 | 2005 | 1378 | 0.010 |
Why?
|